Sapience Therapeutics   Report issue

For profit Phase 1 Phase 2
Founded: New York NY United States (2015)

Organization Overview

First Clinical Trial
2020
NCT04478279
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Sapience Medical Monitor | Sapience Therapeutics

Active Ingredients

Drugs in Phase 2 Trials (1)

st101 (1 trial)

Drugs in Phase 1 Trials (1)

st316 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2